Stephan Schann
Chief Scientific Officer Domain Therapeutics
Stephan Schann is Chief Scientific Officer at Domain Therapeutics. As the leader of Domain’s proprietary programs and collaborations with pharma partners, he oversees the intellectual property strategy for each of the company’s assets. Stephan has been with Domain since its inception in 2008, and his roles have evolved over time, including previous positions as Head of Research, Director of Research & Development and Vice-President of Research & Development.
With over 25 years of experience in biomedical research, Stephan has dedicated his career to the development of novel therapeutics addressing unmet medical needs. His significant contributions to drug discovery and development have been instrumental in shaping Domain’s success and its continuous growth. Prior to joining Domain, Stephan established and led the Medicinal Chemistry Department at Faust Pharmaceuticals and was a senior scientist at Evotec. Stephan holds a PhD in Medical Chemistry from University of Strasbourg in France.
Seminars
- Identifying key differentiating features during drug discovery to overcome the competitive landscape of CCR8-targeted antibodies
- Validating a novel CCR8 antibody candidate with the potential for superior clinical efficacy through strategic design and translational focus
- Highlighting a real-time case study of our CCR8 program, from target validation to first-in-human dosing, illustrating the power of rational antibody design for GPCR therapeutics
